Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Thymoma

NCT06885697 2026-02-17

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

GastrointestinalGynecologicOther solid neoplasmThoracic

Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Thymus Neoplasms

NCT03295227 2026-01-30

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Phase 1 Recruiting

37 enrolled

Thoracic

Thymoma

NCT06838910 2025-12-01

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

Phase 2 Recruiting

20 enrolled

Thoracic

Thymoma

NCT06790706 2025-10-06

IMMUNORARE5

Phase 2 Recruiting

154 enrolled

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT07181720 2025-10-02

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Phase 1 Recruiting

90 enrolled

EndocrineGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thymoma, Thyroid Carcinoma, Anaplastic

NCT05104736 2025-09-19

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Phase 2 Recruiting

53 enrolled

Thoracic

Thymic epithelial tumor, Peripheral Nervous System Diseases, Thymoma, Thymus Neoplasms

NCT03463460 2025-08-24

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Phase 2 Recruiting

30 enrolled

Thoracic

Thymoma

NCT06186726 2025-06-13

Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Phase 2 Recruiting

48 enrolled

Thoracic

Thymoma

NCT06692062 2024-11-18

Hypofractionated Radiotherapy for Thymic Epithelial Tumors

Phase NA Recruiting

100 enrolled

Thoracic

Thymic epithelial tumor, Thymoma, Thymus Neoplasms

NCT06402708 2024-05-10

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Phase 3 Recruiting

172 enrolled

Thoracic

Thymoma

NCT02633553 2023-12-08

Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

Phase NA Recruiting

238 enrolled

Thoracic

Thymoma

NCT02633514 2023-12-05

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Phase 3 Recruiting

1 enrolled

Thoracic

Thymoma

NCT05832827 2023-10-23

Artemis

Phase 2 Recruiting

35 enrolled

Thoracic

Thymoma

NCT04822077 2021-03-30

PROTHYM

Phase NA Recruiting

40 enrolled

Thoracic

Thymoma, Thymus Neoplasms, Cardiotoxicity

Clinical Trials

HEARTS Trial for Thoracic Cancers

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

IMMUNORARE5

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Hypofractionated Radiotherapy for Thymic Epithelial Tumors

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Artemis

PROTHYM